Back to Atlas
APotentially durableResearch-only / high verification need
CMP-0093
Investigational; toxicity-limited
Navitoclax / ABT-263
Senolytic / BCL-2 family
Potent senescent-cell killing in models
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Small molecule
- Primary mechanism
- BCL-2/BCL-xL/BCL-w inhibition removes senescent-cell apoptosis resistance
- Primary market use
- Senolytics / oncology research
Pharmacology
- Molecular weight (Da)
- 974.6
- Oral bioavailability
- Oral; ~56% fed in human PK study
- Half-life
- ~22 h
- Route tags
- Route-dependent / verify
- Evidence level
- Clinical/Preclinical
- Clinical status
- Investigational; toxicity-limited
- Value-for-money score
- 3 / 10
Reported protocol signal
No popular protocol verified yet; keep as reference compound until protocol signal is added.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Strong senolytic but poor value due thrombocytopenia and oncology-grade risk profile